[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Argo Biopharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,64,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100623810","phase-1-study-of-bw-50218-in-healthy-participants-100623810",false,"NCT07401472","Study of BW-50218 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants","Inclusion Criteria:\n\n* Capable of providing written informed consent and complying with all study procedures for the duration of the study.\n* Body weight and body mass index (BMI) within a range considered appropriate for study participation by the investigator.\n* Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.\n* Male participants with partners of childbearing potential must agree to use effective contraception.\n\nExclusion Criteria:\n\n* Any medical condition, recent illness, or laboratory result that, in the investigator's opinion, may increase risk or interfere with participation in the study.\n* Recent hospitalization or a significant acute medical event.\n* History of cancer or any long-term medical condition that the study doctor considers clinically relevant.\n* Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.\n* Positive test for hepatitis B, hepatitis C, or HIV.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants",[28],"Healthy Participants Study","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-03-12",{"date":37,"type":22},"2027-06-30",{"name":39,"class":40},"Shanghai Argo Biopharmaceutical Co., Ltd.","INDUSTRY",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":47,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100640018","phase-1-a-phase-1-clinical-study-in-healthy-participants-100640018","NCT07584876","A Phase 1 Clinical Study in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-41012 in Healthy Participants","Inclusion Criteria:\n\n* Must have given written informed consent and be able to comply with all study requirements\n* Males or females aged 18 to 65 years old, inclusive, at the time of informed consent\n* Body mass index (BMI) ≥18.0 and ≤32.0 kg\u002Fm2 and body weight ≥50.0 kg.\n* APTT, PT, INR, and FXI activity within the normal range at screening\n* Agree to avoid activities that can increase the risk of severe bleeding\n* Female participants must be non-pregnant\n* Male participants with female partners of child-bearing potential must agree to use acceptable methods of contraception from screening until 360 days following administration of the study drug\n\nExclusion Criteria:\n\n* Any clinically significant chronic medical condition or clinically significant abnormality in laboratory parameters\n* Any skin condition and\u002For tattoo\n* Hospitalization for any reason within 60 days prior to screening\n* History or presence of cancer\n* Any clinically significant acute condition\n* Systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg after at least 5 minutes resting\n* Clinical laboratory findings outside of range\n* Any liver function panel analyte value \\> 1.2 × upper limits of normal (ULN)\n* Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody\n* Single 12-lead ECG with clinically significant abnormalities at screening or Day -1\n* Use of an investigational agent\n* .Used of prescription drugs\n* History or clinical evidence of alcohol substance abuse\n* History or clinical evidence of drug abuse\n* Positive test for alcohol or drugs of abuse at screening or Day -1\n* Donated or lost \\>200 mL of blood\n* .Any conditions which, in the opinion of the Investigator",{"count":50,"type":22},40,[25],[53],"HV","NOT_YET_RECRUITING","2026-05-07",{"date":57,"type":33},"2026-05-13",{"date":59,"type":22},"2026-05-15",{"date":61,"type":22},"2028-01-31",{"name":39,"class":40},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":53,"eligibilityCriteria":70,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":63},"100633543","phase-1-a-phase-1-clinical-study-of-bw-20805-2-1001-in-healthy-participants-100633543","NCT07528053","A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants","A Phase 1, Open-Label, Single Dose Bridging Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805-2 in Healthy Participants","Inclusion Criteria:\n\n* Must have given written informed consent and be able to comply with all study requirements\n* Males or females aged 18 to 60 years old, inclusive, at the time of informed consent.\n* Body mass index (BMI) ≥18 and ≤32 kg\u002Fm2 and body weight ≥50 kg Female participants must be non-pregnant\n* Male participants with female partners of child-bearing potential must agree to use acceptable methods of contraception from screening until 48 weeks following administration of the study drug\n\nExclusion Criteria:\n\n* Any clinically significant chronic medical condition or clinically significant abnormality in physical examination that\n* Any skin condition and\u002For tattoo that may interfere with the evaluation of safety at the injection site\n* Hospitalization for any reason within 60 days prior to screening.\n* Presence of carcinoma and history of carcinoma\n* Any clinically significant acute condition\n* Systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg after at least 5 minutes resting\n* Clinical laboratory findings outside of range are deemed clinically significant by the investigator at screening\n* Participants with ANY in clinical laboratory tests at screening or Day-1.\n* History of bleeding diathesis or clinically significant hemorrhagic disorders Positive for hepatitis B surface antigen\n* Single 12-lead ECG with clinically significant abnormalities at screening or Day -1\n* Use of an investigation agent or device within 30 days or 5 half-lives (whichever is longer) before the study drug administration.\n* Used prescription drugs, excluding hormonal contraceptives\n* Used over-the-counter (OTC) medications\n* Have received treatment with small interfering RNA (siRNA) within the last 12 months\n* History of allergic reactions to synthetic siRNA or GalNAc and\u002For any other clinically significant allergic reactions.\n* Use of more than 10 tobacco\u002Fnicotine containing products or equivalent per day within 30 days prior to screening and not willing to abstain for 48 hours prior to admission to the unit\n* History or clinical evidence of alcohol substance abuse, within the 12 months before screening\n* History or clinical evidence of drug abuse, within the 12 months before screening\n* Positive test for alcohol or drugs of abuse at screening or Day -1\n* Have received vaccination with a live vaccine\n* Donated or lost \\>200 mL of blood or plasma within 30 days prior to screening\n* Any conditions which, in the opinion of the Investigator","60 Years",{"count":73,"type":22},24,[25],"A Phase 1 Clinical Study Of BW-20805-2-1001 in Healthy Participants",[53],"2026-04-16",{"date":79,"type":33},"2026-04-21",{"date":81,"type":22},"2026-04-28",{"date":83,"type":22},"2027-11-05",{"name":39,"class":40},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":41},"100586600","phase-1-a-study-to-assess-the-safety-and-effects-of-the-investigational-drug-bw-40202-in-healthy-volunteers-100586600","NCT06917482","A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-40202 in Healthy Subjects","Key inclusion criteria:\n\n1. Must have given written informed consent and be able to comply with all study requirements.\n2. Males or females aged 18 to 60 years old, inclusive, at the time of informed consent.\n3. BMI ≥18 and ≤32 kg\u002Fm2 with 50 kg \\\u003Cbody weight ≤100 kg.\n\nKey exclusion criteria:\n\n1. Any clinically significant chronic medical condition or clinically significant abnormality in laboratory parameters that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.\n2. Hospitalization for any reason within 60 days prior to screening.\n3. Any clinically significant acute condition such as fever (\\>38 degree centigrade) or acute respiratory illness within 14 days of study drug administration.\n4. Systolic blood pressure (more than equal to) 140 mmHg and\u002For diastolic blood pressure (more than equal to) 90 mmHg after at least 5 minutes resting (seated or supine) at screening and Day -1(Repeat blood pressure measurement will be allowed at the discretion of the investigator).\n5. Any liver function panel analyte value \\> 1.2 × upper limits of normal (ULN) which includes aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin (TBIL), alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) at screening.\n6. International normalized ratio (INR) above 1.2 × ULN at screening or Day -1.\n7. Single 12-lead electrocardiogram (ECG) with clinically significant abnormalities at screening or Day -1, asdetermined by the clinical investigator.\n8. History or clinical evidence of alcohol abuse,\n9. History or clinical evidence of drug abuse, within the 12 months before screening.\n10. Donated or lost \\>200 mL of blood within 30 days prior to screening.",{"count":50,"type":22},[25],"This study will test the safety of a new drug called BW-40202 in healthy adults. The drug is a clear liquid given as an injection under the skin (subcutaneous injection). The study will test five different doses of BW-40202 compared to a placebo (saltwater solution).\n\nParticipants will be divided into five groups, with each group receiving a different dose of BW-40202 or placebo. In each group, eight people will be randomly assigned to receive either the drug (6 people) or placebo (2 people).\n\nThe Safety Review Committee will review the safety data before increasing the dose for the next group.\n\nStudy nurses or trained staff will give the injections. Pharmacy staff will keep records of how much drug each participant receives, any returned or destroyed doses, and any changes from the planned dosing schedule. These records will be securely stored and available for review.",[96],"Healthy Volunteers Only","2025-07-22",{"date":99,"type":33},"2025-07-25",{"date":101,"type":33},"2025-06-30",{"date":103,"type":22},"2026-12-31",{"name":39,"class":40},""]